Skip to main content
. 2017 Nov 15;26(146):170066. doi: 10.1183/16000617.0066-2017

TABLE 4.

Main trials published with targeted therapies in nonsmall cell lung cancer with ALK rearrangement

First author
[ref.]
Year Phase Treatment
setting
Previous ALK inhibitor ALK TKI Comparison therapy ORR# % PFS #
months
Solomon [ 40 ] 2014 III First-line No Crizotinib (n=172) Platinum doublet (n=171) 74/45 10.9/7.0
(HR 0.45)
Soria [ 47 ] (ASCEND-4) 2017 III First-line No Ceritinib (n=189) Platinum doublet (n=187) 73/27 16.6/8.1
(HR 0.55)
Hida [48] (J-ALEX) 2017 III Previous
chemotherapy allowed
No Alectinib (n=103) Crizotinib
(n=104)
92/79 Not reached/10.2
(HR 0.34)
Peters [ 49 ] (ALEX) 2017 III First-line No Alectinib (n=152) Crizotinib
(n=151)
83/76 Not reached/11.1
(HR 0.47)
Shaw [ 39 ] 2013 III Second-line No Crizotinib (n=173) Pemetrexed
(n=174)
65/20 7.7/3.0
(HR 0.49)
Shaw [42] 2014 I Any lines Accepted Ceritinib ≥400 mg (n=114) 58 7.0
Any lines Crizotinib Ceritinib (n=80) 56 6.9
Shaw [ 43 ] 2016 II Any lines Crizotinib Alectinib (n=69) 48 8.1
Gettinger [ 45 ] 2016 I/II Any lines Accepted Brigatinib (n=52) 77
Any lines No Brigatinib (n=4) 100 Not reached
Any lines Crizotinib Brigatinib (n=52) 74 14.5
Any lines Accepted but brain metastasis Brigatinib (n=6) 83 No event

ALK: anaplastic lymphoma kinase; TKI: tyrosine kinase inhibitor; ORR: objective response rate; PFS: progression-free survival; HR: hazard ratio. #: comparisons presented as ALK TKI/comparison therapy.